L

Lytix Biopharma AS
OSE:LYTIX

Watchlist Manager
Lytix Biopharma AS
OSE:LYTIX
Watchlist
Price: 6.88 NOK 0.88% Market Closed
Market Cap: 341.3m NOK
Have any thoughts about
Lytix Biopharma AS?
Write Note

Lytix Biopharma AS
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Lytix Biopharma AS
Cash & Cash Equivalents Peer Comparison

Comparables:
HBC
B
BGBIO
AZT
N
NYKD
T
TRMED

Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
L
Lytix Biopharma AS
OSE:LYTIX
Cash & Cash Equivalents
kr27.4m
CAGR 3-Years
-1%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
Hofseth Biocare ASA
OSE:HBC
Cash & Cash Equivalents
kr25.3m
CAGR 3-Years
-39%
CAGR 5-Years
5%
CAGR 10-Years
20%
B
Bergenbio ASA
OSE:BGBIO
Cash & Cash Equivalents
kr200.1m
CAGR 3-Years
-30%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
Arcticzymes Technologies ASA
OSE:AZT
Cash & Cash Equivalents
kr170.3m
CAGR 3-Years
-1%
CAGR 5-Years
51%
CAGR 10-Years
7%
N
Nykode Therapeutics ASA
OSE:NYKD
Cash & Cash Equivalents
$136.5m
CAGR 3-Years
-8%
CAGR 5-Years
29%
CAGR 10-Years
N/A
T
Thor Medical ASA
OSE:TRMED
Cash & Cash Equivalents
kr29.6m
CAGR 3-Years
-60%
CAGR 5-Years
-42%
CAGR 10-Years
-5%

See Also

What is Lytix Biopharma AS's Cash & Cash Equivalents?
Cash & Cash Equivalents
27.4m NOK

Based on the financial report for Dec 31, 2023, Lytix Biopharma AS's Cash & Cash Equivalents amounts to 27.4m NOK.

What is Lytix Biopharma AS's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-11%

Over the last year, the Cash & Cash Equivalents growth was -71%. The average annual Cash & Cash Equivalents growth rates for Lytix Biopharma AS have been -1% over the past three years , -11% over the past five years .

Back to Top